Indication
Influenza Immunization
20 clinical trials
37 products
Clinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High Dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2023/24Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of One Monovalent Modified Influenza mRNA Vaccine Encapsulated in LNP, in Adults Aged 18 to 49 Years and 60 Years and Above.Status: Completed, Estimated PCD: 2024-03-14
Clinical trial
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared With Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.Status: Terminated, Estimated PCD: 2023-10-03
Product
H3 mRNA / LNP VaccineClinical trial
Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2024-01-03
Product
mRNA NA vaccineClinical trial
A Phase I Study to Assess the Safety, Reactogenicity and Immunogenicity of Two Quadrivalent Seasonal Influenza Vaccines (Fluzone(R) or Flublok(R)) With or Without One of Two Adjuvants (AF03 or Advax-CpG55.2) in Healthy Adults 18-45 Years of AgeStatus: Completed, Estimated PCD: 2020-09-18
Clinical trial
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years.Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2024-04-02
Clinical trial
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and AboveStatus: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2024-03-28
Clinical trial
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2024-01-19
Clinical trial
A Phase II, Open-label Study to Assess the Safety and Immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 VaccineStatus: Completed, Estimated PCD: 2022-02-08
Product
COVID-19 mRNA VaccineClinical trial
Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in JapanStatus: Completed, Estimated PCD: 2021-01-14
Clinical trial
Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose Quadrivalent, Influenza Vaccines, 2021-2022 FormulationsStatus: Completed, Estimated PCD: 2021-11-10
Clinical trial
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and OlderStatus: Completed, Estimated PCD: 2020-01-09
Product
Fluzone QuadrivalentClinical trial
Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose Quadrivalent, Influenza Vaccines, 2020-2021 FormulationsStatus: Completed, Estimated PCD: 2020-12-18
Clinical trial
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens Without or With Adjuvant in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2021-09-20
Product
Quadrivalent RIVClinical trial
A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 AdjuvantStatus: Completed, Estimated PCD: 2019-09-26
Product
AS03Clinical trial
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza VaccinationStatus: Terminated, Estimated PCD: 2020-03-31
Product
AF03Product
Delta Inulin-CpG55.2Clinical trial
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy VolunteersStatus: Terminated, Estimated PCD: 2019-12-06